Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Spinifex Pharmaceuticals closes $45mm Series C financing

Executive Summary

Australian biotech Spinifex Pharmaceuticals Pty. Ltd. raised $45mm in a Series C financing led by new investor Novo AS, which was joined by another first-time backer Canaan Partners and returning shareholders GBS Venture Partners, Brandon Capital Partners, Uniseed, and UniQuest. Members from Novo and Canaan took seats on Spinifex’s board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies